Home > Healthcare > Biotechnology > Biotechnology R&D > Non-animal Alternative Testing Market

Non-animal Alternative Testing Market Trends

Report ID: GMI5704
Published Date: Oct 2024
Report Format: PDF

Download Free Sample

Non-animal Alternative Testing Market Trends

Technological advances in drug development are playing a significant role in driving the growth of the industry. These innovations have shifted the paradigm of traditional animal testing, enabled the creation of safer and more effective drugs while addressing ethical concerns.

One of the most prominent advances is the rise of in silico models, which use computer-based simulations to predict how drugs will interact with human tissues. These computational approaches, such as quantitative structure-activity relationship (QSAR) models, are gaining traction due to their ability to assess chemical toxicity without animal testing. This is supported by advancements in artificial intelligence (AI) and machine learning, which allow for better predictive models by analyzing vast amounts of biological and chemical data.
Furthermore, 3D cell cultures and tissue-engineering techniques are also gaining momentum, providing more realistic models for drug testing. These innovations allow for the cultivation of human tissues in three dimensions, offering a closer approximation to in-vivo conditions compared to traditional 2D cultures. These technological advances are helping the industry grow, as they offer cost-effective, ethical, and accurate alternatives to animal models.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global non-animal alternative testing industry was valued at approximately USD 1.8 billion in 2023 and is estimated to grow at an 11.9% CAGR from 2024 to 2032, driven by increasing investments and research grants for alternative technologies.

The cell lines segment dominated the market in 2023, accounting for USD 1.2 billion, due to their extensive use in drug development, toxicity testing, and biological research.

The U.S. non-animal alternative testing industry is forecasted to reach USD 1.9 million by 2032, having dominated the North American market with a revenue of USD 656.6 million in 2023.

Increasing public awareness and ethical concerns about animal testing are driving pharmaceutical companies to adopt non-animal testing methods, influenced by consumer demand for more humane research practices.

Key players in the industry include AlveoliX, BICO GROUP, CN Bio Innovations, Emulate, Hesperos, InSphero, Lonza Group, Merck, MIMETAS, Thermo Fisher Scientific, TissUse, and VITROCELL Systems.